Evidence map›Paper›PMID 29333143›Full record

ArticleEJIFCC2017

Task Force on CKD - We have Come a Long Way.

Graham R D Jones

Abstract read
In one paragraph

Article in EJIFCC, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Graham R D JonesDepartment of Chemical Pathology, SydPath, St Vincent's Hospital, Sydney, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic Kidney Disease (CKD) is an important medical condition where diagnosis, staging and monitoring is largely based on routine laboratory tests. During the last 15 years there have been many important changes in the clinical management of CKD described in key international guidelines. In order to successfully implement these guidelines, laboratories must collaborate with clinicians to provide a co-ordinated service, including accurate measurements and of creatinine and urine albumin and reporting of an estimated glomerular filtration rate (eGFR). The IFCC/WASPaLM Task Force on Chronic Kidney Disease (TF-CKD) was established in 2008 and since that time has worked to improve laboratory testing in CKD. Key aspects of the work of the TF-CKD include supporting national laboratory medicine organisations to develop CKD testing guidelines, recognition of the vital role of collaboration between laboratory and clinical organisations, the importance of accurate measurements, and endorsement of the KDIGO 2012 CKD guidelines. A key function of the TF-CKD has been to facilitate sharing and learning between countries to provide the best outcomes.

Indexed as

calibrationreference measurement procedurestandardizationurine albumin

Identifiers

PMID29333143
PMCPMC5746833

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.